open access

Vol 2, No 3 (2006)
Review paper
Published online: 2006-06-30
Get Citation

Rituximab in the treatment of follicular lymphoma

Wojciech Jurczak, Jan Walewski
Onkol. Prak. Klin 2006;2(3):117-126.

open access

Vol 2, No 3 (2006)
REVIEW ARTICLES
Published online: 2006-06-30

Abstract

Despite previous observations, recent epidemiological and retrospective data show improvement in follicular lymphoma (FL) outcome, due to increased use of polychemotherapy in the last 20 years, even before the era of rituximab. Chemoimmunotherapy with rituximab - an anti CD20 monoclonal antibody - is an undisputable outbreak and one of the rare examples of novel treatment modalities, were an increased antineoplastic efficiency is achieved literally without any additional toxicity. Numerous, international randomized studies (conducted with participation of Polish centers) demonstrated statistically important benefit, of the addition of rituximab: it increased remission rate, remission duration and overall survival. It also results in an important improvement of life quality of the patients: fewer and less frequent relapses means less exposure to toxic and mostly inefficient chemotherapy regimens. Therefore including rituximab in an induction chemotherapy and later in subsequent consolidation is a recommended treatment of choice in follicular lymphoma. This recommendation is based on several phase III studies, were over 3000 patients we randomized. In this review paper, we present the results of recent, most important clinical trials in FL.

Abstract

Despite previous observations, recent epidemiological and retrospective data show improvement in follicular lymphoma (FL) outcome, due to increased use of polychemotherapy in the last 20 years, even before the era of rituximab. Chemoimmunotherapy with rituximab - an anti CD20 monoclonal antibody - is an undisputable outbreak and one of the rare examples of novel treatment modalities, were an increased antineoplastic efficiency is achieved literally without any additional toxicity. Numerous, international randomized studies (conducted with participation of Polish centers) demonstrated statistically important benefit, of the addition of rituximab: it increased remission rate, remission duration and overall survival. It also results in an important improvement of life quality of the patients: fewer and less frequent relapses means less exposure to toxic and mostly inefficient chemotherapy regimens. Therefore including rituximab in an induction chemotherapy and later in subsequent consolidation is a recommended treatment of choice in follicular lymphoma. This recommendation is based on several phase III studies, were over 3000 patients we randomized. In this review paper, we present the results of recent, most important clinical trials in FL.
Get Citation

Keywords

follicular lymphoma; rituximab; immunochemotherapy

About this article
Title

Rituximab in the treatment of follicular lymphoma

Journal

Oncology in Clinical Practice

Issue

Vol 2, No 3 (2006)

Article type

Review paper

Pages

117-126

Published online

2006-06-30

Bibliographic record

Onkol. Prak. Klin 2006;2(3):117-126.

Keywords

follicular lymphoma
rituximab
immunochemotherapy

Authors

Wojciech Jurczak
Jan Walewski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl